Intensity Therapeutics Inc

NASDAQ:INTSUnited States

Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. The Company is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead investigational product candidate, INT230-6, is designed for direct intratumoral injection. Its INT230-6 is primarily comprised of three components: cisplatin, vinblastine sulfate and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of Phase III open-label, randomized study testing the superiority of INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, and Phase II/III clinical study in metastatic triple negative breast cancer.

Contact Information

Headquarters

1 Enterprise Drive, Suite 430SHELTON, CT, United States 06484

Phone

203-221-7381

Fax

302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer

Lewis Bender

Chief Financial Officer

Joseph Talamo

Principal Accounting Officer, Controller

John Wesolowski

Independent Director

Daniel Donovan

Independent Director

Thomas Dubin